Third-party testimony could turn tide in US FTC’s challenge of Edwards-JenaValve
By Wesley Brown ( December 11, 2025, 17:43 GMT | Comment) -- Third-party testimony piecing together the market for transcatheter aortic valve replacement devices in the United States, much of which was sealed during trial, could be key in the US Federal Trade Commission’s bid to block Edwards Lifesciences’ acquisition of JenaValve. Judge Rudolph Contreras of the US District Court for the District of Columbia presided over the government’s challenge late last month which saw 10.5 hours of sealed testimony across about 41 hours of hearings, nearly one-quarter of all testimony given.Third-party testimony piecing together the market for transcatheter aortic valve replacement devices in the United States, much of which was sealed during trial, could be key in the US Federal Trade Commission’s bid to block Edwards Lifesciences’ acquisition of JenaValve....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.